LONDON – One of the UK's oldest biotech companies looks to be on its way out after reporting the failure of the lead program in Parkinson's disease. Read More
A partnership between Roche AG and Chiasma Inc., of New York, promises to take the pain out of therapy for acromegaly, the overproduction of growth hormone. Read More
Aiming to start pivotal trials with its therapy for benign prostatic hyperplasia (BPH) before the end of the year, Sophiris Bio Inc. (formerly Protox Therapeutics Inc.) filed for an initial public offering (IPO) that specifies neither the number of shares nor the price range. Read More
LONDON – 2013 will be a watershed year for biosimilars – biological therapies designed to be similar to existing biological therapeutic agents – delegates attending the Second Biosimilars Congregation in London heard Tuesday. Read More
BOSTON – Regenerative medicine pioneer Paolo Macchiarini is now taking the field to its ultimate heights – and into the realms of science fiction – embarking on a brain regeneration project. Read More
BOSTON – The rise in the number of new drug approvals granted by the FDA in the past three years looks encouraging – hinting as it does that the industry is putting the productivity woes of the previous decade behind it. Read More
• Galectin Therapeutics Inc., of Norcross, Ga., said it established a drug discovery program in collaboration with Geert-Jan Boons' lab at the University of Georgia to discover new carbohydrate molecules that can be used in the therapy of diseases where galectin proteins play a major role, including cancer and inflammatory and fibrotic disorders. Read More
• C3 Jian Inc., of Los Angeles, said it completed enrollment in a Phase I study testing C16G2, a synthetic peptide derived from its pheromone signaling platform technology called STAMPS (Specifically Targeted Antimicrobial Peptides). Read More
• Novartis AG, of Basel, Switzerland, said the FDA approved mTOR inhibitor Zortress (everolimus) for the prophylaxis of organ rejection in adults receiving liver transplants. Read More
